```html

Fifth Disease (Erythema Infectiosum) – A Complete Medical Guide

Overview

Fifth disease, also called erythema infectiosum, is a common viral infection caused by human parvovirus B19. It is named “fifth” because it was the fifth of the classic childhood exanthems described in the early 20th century (the others being measles, scarlet fever, rubella, and roseola).

• Typical age group: Children 5–15 years old, but it can affect infants, adults, and even the elderly.
• Prevalence: In the United States, seroprevalence studies show that up to 70 % of adults have antibodies to parvovirus B19, indicating prior infection (CDC, 2023). Seasonal peaks occur in late winter and early spring.
• Transmission: Primarily through respiratory droplets (coughing, sneezing) or direct contact with infected blood. The virus can survive on surfaces for several days.

Most infections are mild, self‑limited, and resolve without complications. However, certain populations—pregnant women, people with weakened immune systems, or those with underlying blood disorders—are at higher risk for severe outcomes.

Symptoms

Symptoms evolve in three stages. Not every patient experiences all stages.

Stage 1 – Incubation (4–14 days)

• Often asymptomatic; the virus replicates in the bone marrow.
• Low‑grade fever (≤38 °C/100.4 °F).
• General malaise, mild headache, or sore throat.

Stage 2 – “Slapped‑Cheek” Rash (2–5 days)

• Facial erythema: Bright red, flat or slightly raised rash on cheeks that gives the classic “slapped‑cheek” appearance.
• Rash may be more pronounced after exposure to heat, sunlight, or emotional stress.
• Low‑grade fever may persist.

Stage 3 – Lacy Body Rash (5‑10 days, may last weeks)

• Fine, reticular (lace‑like) erythematous rash on the trunk, arms, and legs. It can be itchy.
• Rash may wax and wane with temperature changes.
• Joint pain or swelling, especially in adolescents and adults (knees, wrists, ankles).

Other possible manifestations

• Transient swelling of the lymph nodes.
• Rarely, an aplastic crisis (sudden drop in red blood cell production) in patients with hemolytic anemias.
• In pregnant women, possible fetal hydrops or miscarriage (see Complications).

Causes and Risk Factors

Human parvovirus B19 is the sole causative agent. It has a strong affinity for erythroid progenitor cells in the bone marrow, which explains its potential effect on blood formation.

How the virus spreads

• Respiratory droplets when an infected person coughs or sneezes.
• Direct contact with saliva, nasal secretions, or blood.
• Rarely, vertical transmission from mother to fetus during pregnancy.

Risk factors for infection

• Age: School‑age children are most exposed due to close contact in classrooms.
• Living conditions: Crowded households, daycare centers, or schools increase transmission.
• Immunocompromised state: HIV, organ transplant recipients, chemotherapy patients have higher risk of prolonged infection.
• Pre‑existing hemolytic disorders: Sickle cell disease, thalassemia, hereditary spherocytosis increase risk of severe anemia.
• Pregnancy: While pregnant women can become infected, the fetus is at risk for complications.

Diagnosis

Diagnosis is primarily clinical, supported by laboratory tests when the presentation is atypical or complications are suspected.

Clinical assessment

• History of exposure to infected individuals or outbreaks.
• Physical exam noting the characteristic facial “slapped‑cheek” rash and subsequent lacy rash.
• Evaluation for joint pain, fever, or hematologic symptoms.

Laboratory tests

• Serology: Detection of IgM antibodies (appears 1‑2 weeks after infection, persists ~3 months) confirms recent infection; IgG indicates past exposure and immunity.
• Polymerase Chain Reaction (PCR): Detects viral DNA in blood, bone‑marrow, or respiratory secretions. Preferred for immunocompromised patients where antibody response may be blunted.
• Complete blood count (CBC): May show transient anemia, leukopenia, or thrombocytopenia; in patients with hemolytic anemia, a sudden drop in hemoglobin suggests aplastic crisis.
• Bone‑marrow aspirate (rare): Shows atypical giant pronormoblasts; used only when diagnosing persistent infection.

Treatment Options

There is no specific antiviral therapy for parvovirus B19. Management is symptomatic and supportive, with special considerations for high‑risk groups.

Supportive care

• Rest and hydration.
• Acetaminophen or ibuprofen for fever and joint pain (avoid aspirin in children).
• Cool compresses or antihistamine creams for itchiness.

Pharmacologic interventions

• Immunoglobulin (IVIG): Intravenous immunoglobulin is effective for chronic infection in immunocompromised patients or severe aplastic crisis. Typical dose: 0.4 g/kg daily for 5 days (CDC, 2022).
• Blood transfusion: Indicated for severe anemia or aplastic crisis, especially in patients with underlying hemolytic disease.
• Folic acid supplementation: May aid erythropoiesis in patients with anemia.

Lifestyle measures

• Stay home until the facial rash fades (usually 5‑7 days) to limit spread.
• Practice good hand hygiene and cover mouth when coughing.
• Avoid sharing utensils, drinks, or personal items during the contagious period.

Living with Fifth disease (Erythema infectiosum)

Most people recover completely within 2‑4 weeks. Below are practical tips for daily life during and after infection.

• School/Work: Children can return to school once the facial rash resolves; however, the lacy body rash may persist without being contagious.
• Hydration & nutrition: Encourage fluids, iron‑rich foods (lean meats, leafy greens) and vitamin C to support the immune system.
• Joint discomfort: Low‑impact exercise (e.g., walking, swimming) and warm baths can relieve stiffness.
• Monitoring: Parents should watch for a sudden drop in energy, pallor, or rapid breathing, which could signal anemia.
• Pregnancy: Women who develop a rash during pregnancy should contact their obstetrician immediately for serologic testing.
• Immunocompromised patients: Follow-up labs (CBC, PCR) every 2‑4 weeks until viral clearance is confirmed.

Prevention

Because there is no vaccine for parvovirus B19, prevention relies on general infection‑control practices.

• Hand hygiene: Wash hands with soap and water for at least 20 seconds, especially after coughing, sneezing, or touching shared surfaces.
• Respiratory etiquette: Use tissues or elbows to cover coughs/sneezes; discard tissues promptly.
• Isolation: Keep children with a “slapped‑cheek” rash at home until the rash fades.
• Environmental cleaning: Disinfect toys, desks, and shared equipment daily with EPA‑registered disinfectants.
• Avoid blood exposure: Use universal precautions when handling blood or bodily fluids (e.g., during first aid).
• Pregnant women: Limit close contact with children known to have fifth disease during outbreaks; discuss serology with a healthcare provider if exposure occurs.

Complications

While rare, complications can be serious, especially in vulnerable groups.

• Aplastic crisis: Sudden cessation of red‑cell production can lead to severe anemia; seen in patients with chronic hemolysis (sickle cell disease, thalassemia).
• Chronic anemia: Persistent low hemoglobin in immunocompromised patients.
• Hydrops fetalis & miscarriage: Maternal infection during the first half of pregnancy can cause fetal anemia, hydrops, or intrauterine death (reported in ~0.5 % of maternal infections; WHO, 2021).
• Arthropathy: Adults may develop prolonged joint pain lasting months, mimicking rheumatoid arthritis.
• Neurologic involvement: Very rare cases of encephalitis, Guillain‑Barré syndrome, or peripheral neuropathy have been reported.

When to Seek Emergency Care

References

• Centers for Disease Control and Prevention (CDC). “Parvovirus B19 (Fifth Disease).” 2023. https://www.cdc.gov/parvovirusb19/
• World Health Organization (WHO). “Parvoviruses in humans.” 2021.
• Mayo Clinic. “Fifth disease (erythema infectiosum).” 2022.
• Cleveland Clinic. “Parvovirus B19 infection.” 2023.
• National Institutes of Health (NIH). “Parvovirus B19.” MedlinePlus, 2022.
• Stöckl, D. et al. “Aplastic crisis in sickle cell disease caused by parvovirus B19.” *Blood*, 2020.

```